Probiotic in the Prevention of Ventilator-associated Pneumonia in Critically Ill Patients: Evidence from Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials
Overview
Affiliations
Background: Probiotic might have a role in the prevention of ventilator-associated pneumonia (VAP) among mechanically ventilated patients, but the efficacy and safety remained inconsistent. The aim of this systematic review and meta-analysis was to evaluate the efficacy and safety of probiotic (prebiotic, synbiotic) versus placebo in preventing VAP in critically ill patients undergoing mechanical ventilation.
Methods: PubMed, Embase and the Cochrane library databases were searched to 10 October 2021 without language restriction for randomized or semi-randomized controlled trials evaluating probiotic (prebiotic, synbiotic) vs. placebo in prevention of VAP in critically ill mechanically ventilated patients. The pooled relative risk (RR) along with 95% confidence intervals (CI) were combined using a random-effects model. Furthermore, the trial sequential analysis (TSA) and subgroup analyses were performed. Statistical significance was regarded as P < 0.05.
Results: Twenty-three trials involving 5543 patients were eligible for this meta-analysis. The combined RR of decreasing the risk of VAP by probiotic was 0.67 (0.56, 0.81) for all eligible studies, 0.69 (n = 5136; 95% CI = 0.57 to 0.84; P < 0.01) for adults studies and 0.55 (n = 407; 95%CI = 0.31 to 0.99; P = 0.046) for neonates/children studies. Additionally, the above-mentioned positive finding in 20 adults studies was verified by the results of TSA, subgroup analyses and cumulative meta-analysis. Ample evidences demonstrated a 31% decrease in RR of incidence of VAP was noted when prophylactic probiotic therapy was administrated among adult patients. Finally, there were no effects on the ICU/hospital/28-/90-day mortality, bacteremia, CRBSI, diarrhea, ICU-acquired infections, infectious complications, pneumonia, UTI and wound infection between two groups (P > 0.05 for all).
Conclusions: Based on the results of our study, the current evidences suggested that prophylactic administration of probiotic might be utilized as a preventive method for VAP in neonates/children and adults patients who required mechanical ventilation. However, further large, high-quality RCTs are warranted to assess the efficacy and safety of probiotic treatment in critically ill patients, especially for the neonates/children studies and the long-term consequences of this therapy.
Preventing ventilator-associated pneumonia non-pharmacologically.
Krone M, Seeber C, Nydahl P Intensive Care Med. 2024; 50(12):2185-2187.
PMID: 39476021 PMC: 11588847. DOI: 10.1007/s00134-024-07696-x.
The spectrum of pneumonia among intubated neonates in the neonatal intensive care unit.
Bondarev D, Ryan R, Mukherjee D J Perinatol. 2024; 44(9):1235-1243.
PMID: 38698211 PMC: 11379627. DOI: 10.1038/s41372-024-01973-9.
Prevention of ventilator-associated pneumonia with probiotics: an overview of systematic reviews.
Han M, Wang K, Sun L, Liu W, Dong W Front Microbiol. 2024; 15:1345278.
PMID: 38426068 PMC: 10902917. DOI: 10.3389/fmicb.2024.1345278.
Onofrei M, Ghiciuc C, Luca C, Postolache P, Sapaniuc C, Enache Leonte G Medicina (Kaunas). 2023; 59(3).
PMID: 36984479 PMC: 10056847. DOI: 10.3390/medicina59030478.
Roshanzamiri S, Alemzadeh M, Narjes Ahmadizadeh S, Behzad A, Hashemi S, Salamzadeh J Front Pediatr. 2022; 10:1045941.
PMID: 36458140 PMC: 9705346. DOI: 10.3389/fped.2022.1045941.